Lifecore Biomedical, Inc.
LFCRHealthcare|Drug Manufacturers - Specialty & Generic|US
$6.36
-0.04 (-0.63%)
Cash / Share
$0.61
Financials
Financial Snapshot
Market Cap
$241.1M
Enterprise Value
$441.2M
Revenue (TTM)
$116.8M
Net Income (TTM)
-$67.4M
Cash & Investments
$23.0M
Net Cash
-$200.1M
Free Cash Flow (TTM)
$5.1M
Operating CF (TTM)
$9.8M
Debt/Equity
-3.04
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.4M | $2.9M | $1.1M | $360.0K | $1.2M | $991.0K | $19.1M | $8.5M | $8.3M | $17.5M | $23.0M | |
| Operating Cash Flow | $29.3M | $19.8M | $16.0M | -$17.0M | $16.5M | -$22.6M | -$17.4M | $257.0K | -$206.0K | $12.6M | $9.8M | |
| Free Cash Flow | $6.7M | -$13.8M | -$28.7M | -$43.7M | -$8.8M | -$52.5M | -$38.9M | -$18.1M | -$13.6M | $6.2M | $5.1M | |
| Capital Expenditure | -$22.6M | -$33.6M | -$44.7M | -$26.7M | -$25.2M | -$29.9M | -$21.5M | -$18.4M | -$13.4M | -$6.3M | -$4.7M | |
| Financing Cash Flow | -$8.8M | $13.3M | $79.0M | $40.0M | -$3.4M | -$57.0M | $39.7M | $7.5M | $6.4M | -$1.1M | -$5.8M |
R&D Spending
R&D (TTM)
$5.7M
R&D Intensity
4.9%
R&D Growth vs Prior
-32.8%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $532.3M | $524.2M | $557.6M | $160.1M | $100.9M | $111.3M | $103.3M | $128.3M | $128.9M | $129.5M | $116.8M | |
| R&D Expense | $9.5M | $12.8M | $11.5M | $7.6M | $6.7M | $7.8M | $8.7M | $8.6M | $8.3M | $8.5M | $5.7M | |
| R&D % of Revenue | 1.8% | 2.4% | 2.1% | 4.7% | 6.6% | 7.0% | 8.5% | 6.7% | 6.4% | 6.6% | 4.9% | |
| SG&A | $58.2M | $52.0M | $64.1M | $40.7M | $27.7M | $34.7M | $39.0M | $40.5M | $44.0M | $33.4M | $30.2M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $532.3M | $524.2M | $557.6M | $160.1M | $100.9M | $111.3M | $103.3M | $128.3M | $128.9M | $129.5M | $116.8M | |
| Cost of Revenue | $449.1M | $445.9M | $476.6M | $120.7M | $61.9M | $72.2M | $75.3M | $86.4M | $88.6M | $88.9M | $81.4M | |
| Gross Profit | $83.2M | $78.3M | $81.0M | $39.4M | $38.9M | $39.1M | $28.0M | $41.9M | $40.3M | $40.6M | $35.4M | |
| R&D | $9.5M | $12.8M | $11.5M | $7.6M | $6.7M | $7.8M | $8.7M | $8.6M | $8.3M | $8.5M | $5.7M | |
| SG&A | $58.2M | $52.0M | $64.1M | $40.7M | $27.7M | $34.7M | $39.0M | $40.5M | $44.0M | $33.4M | $30.2M | |
| Operating Income | $15.5M | $11.8M | -$8.0M | -$25.9M | -$8.8M | -$11.8M | -$21.8M | -$8.8M | -$17.2M | -$1.3M | -$432.0K | |
| Interest Expense | $1.8M | $1.9M | $5.2M | $4.6M | $8.9M | $15.6M | $17.6M | $18.1M | $21.8M | -$2.2M | $30.9M | |
| Pretax Income | $15.0M | $16.4M | $3.6M | -$30.6M | -$29.8M | -$20.7M | -$63.9M | $9.5M | -$38.7M | -$30.2M | -$67.2M | |
| Net Income | $10.6M | $24.8M | $2.1M | -$38.2M | -$32.3M | -$116.7M | -$99.6M | $12.0M | -$38.7M | -$30.8M | -$67.4M | |
| EPS (Diluted) | 0.38 | 0.89 | 0.07 | -1.31 | -1.12 | -3.97 | -3.32 | 0.33 | -1.27 | -0.93 | -1.89 | |
| EBITDA | $26.7M | $26.0M | $24.1M | -$7.2M | -$987.0K | $12.8M | -$33.2M | $35.6M | -$8.8M | $8.2M | -$28.9M | |
| Shares Out. (M) | 27.65 | 27.91 | 28.61 | 29.16 | 29.29 | 29.47 | 29.96 | 36.66 | 34.82 | 37.37 | 37.85 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.4M | $2.9M | $1.1M | $360.0K | $1.2M | $991.0K | $19.1M | $8.5M | $8.3M | $17.5M | $23.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $81.3M | $97.1M | $133.0M | $157.1M | $148.3M | $116.7M | $93.9M | $81.0M | $85.7M | $82.3M | $84.7M | |
| Total Assets | $358.0M | $404.7M | $519.1M | $541.3M | $502.9M | $274.7M | $253.5M | $254.0M | $239.3M | $232.2M | $228.3M | |
| Total Current Liabilities | $51.5M | $88.4M | $137.1M | $164.4M | $101.9M | $176.6M | $39.3M | $38.9M | $30.2M | $23.6M | $22.0M | |
| Long-Term Debt | $42.3M | $37.4M | $87.7M | $101.4M | $164.9M | $97.6M | $101.1M | $123.7M | $127.0M | $135.6M | $222.2M | |
| Total Liabilities | $129.9M | $152.1M | $248.9M | $310.3M | $300.1M | $186.9M | $257.8M | $242.6M | $238.0M | $246.4M | $250.6M | |
| Stockholders' Equity | $226.6M | $252.6M | $270.1M | $231.0M | $202.8M | $87.8M | -$4.2M | $11.3M | $1.3M | -$14.2M | -$73.4M | |
| Retained Earnings | $84.5M | $109.3M | $109.7M | $71.2M | $38.6M | -$79.0M | -$178.5M | -$166.5M | -$205.2M | -$223.2M | -$284.4M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $29.3M | $19.8M | $16.0M | -$17.0M | $16.5M | -$22.6M | -$17.4M | $257.0K | -$206.0K | $12.6M | $9.8M | |
| Capital Expenditure | -$22.6M | -$33.6M | -$44.7M | -$26.7M | -$25.2M | -$29.9M | -$21.5M | -$18.4M | -$13.4M | -$6.3M | -$4.7M | |
| Free Cash Flow | $6.7M | -$13.8M | -$28.7M | -$43.7M | -$8.8M | -$52.5M | -$38.9M | -$18.1M | -$13.6M | $6.2M | $5.1M | |
| Investing Cash Flow | -$25.0M | -$35.6M | -$96.8M | -$23.9M | -$12.3M | $80.0M | -$4.8M | -$18.4M | -$6.4M | -$1.6M | $5.3M | |
| Financing Cash Flow | -$8.8M | $13.3M | $79.0M | $40.0M | -$3.4M | -$57.0M | $39.7M | $7.5M | $6.4M | -$1.1M | -$5.8M | |
| Issuance of Stock | $706.0K | $56.0K | $327.0K | $30.0K | $0.00 | $0.00 | $4.8M | $0.00 | $23.9M | $0.00 | -$614.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.9M | -$615.0K | |
| Net Debt Issuance | -$8.6M | $18.9M | $54.9M | $41.8M | $7.5M | -$55.4M | $3.1M | $2.2M | -$18.6M | -$17.2M | -$2.5M | |
| Stock Based Comp. | $4.0M | $4.4M | $3.6M | $2.4K | $3.4M | $2.6M | $3.6M | $6.2M | $10.2M | $6.2M | $11.4M | |
| Net Change in Cash | -$4.5M | -$2.5M | -$1.8M | -$912.0K | $742.0K | $348.0K | $17.4M | -$10.6M | -$197.0K | -$197.0K | $12.6M |
Dilution Tracker
Shares outstanding grew 27.6% over 5 years — significant dilution
Shares Outstanding
38M
5-Year Share Growth
+27.6%
Stock Issuance (TTM)
-$614.0K
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 27.65 | 27.91 | 28.61 | 29.16 | 29.29 | 29.47 | 29.96 | 36.66 | 34.82 | 37.37 | 37.85 | |
| Change vs Prior % | — | 1.0% | 2.5% | 1.9% | 0.5% | 0.6% | 1.7% | 22.4% | -5.0% | 7.3% | 1.3% | |
| Stock Issuance | $706.0K | $56.0K | $327.0K | $30.0K | $0.00 | $0.00 | $4.8M | $0.00 | $23.9M | $0.00 | -$614.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.9M | -$615.0K | |
| Stock Based Comp. | $4.0M | $4.4M | $3.6M | $2.4K | $3.4M | $2.6M | $3.6M | $6.2M | $10.2M | $6.2M | $11.4M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 15.6% | 14.9% | 14.5% | 24.6% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% | 31.4% | 30.3% | |
| Operating Margin % | 2.9% | 2.3% | -1.4% | -16.2% | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% | -1.0% | -0.4% | |
| Net Margin % | 2.0% | 4.7% | 0.4% | -23.9% | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% | -23.8% | -57.7% | |
| EBITDA Margin % | 5.0% | 5.0% | 4.3% | -4.5% | -1.0% | 11.5% | -32.1% | 27.7% | -6.8% | 6.4% | -24.8% | |
| FCF Margin % | 1.3% | -2.6% | -5.1% | -27.3% | -8.7% | -47.2% | -37.7% | -14.1% | -10.6% | 4.8% | 4.4% | |
| ROE % | 4.7% | 9.8% | 0.8% | -16.5% | -15.9% | -132.9% | 2353.7% | 106.2% | -2898.0% | 216.8% | 381.6% | |
| ROA % | 3.0% | 6.1% | 0.4% | -7.1% | -6.4% | -42.5% | -39.3% | 4.7% | -16.2% | -13.3% | -29.5% | |
| ROIC % | 3.5% | 3.4% | -1.1% | -3.9% | -1.6% | -3.7% | -10.1% | -3.9% | -8.1% | -0.6% | -0.2% | |
| R&D / Revenue % | 1.8% | 2.4% | 2.1% | 4.7% | 6.6% | 7.0% | 8.5% | 6.7% | 6.4% | 6.6% | 4.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.6% | -1.5% | 6.4% | -71.3% | -37.0% | 10.3% | -7.2% | 24.2% | 0.5% | 0.5% | |
| Gross Profit | 17.2% | -5.8% | 3.4% | -51.4% | -1.1% | 0.3% | -28.4% | 49.5% | -3.7% | 0.8% | |
| Operating Income | 178.4% | -23.6% | -167.6% | -223.0% | 65.9% | -33.6% | -84.9% | 59.4% | -95.0% | 92.7% | |
| Net Income | 191.0% | 134.5% | -91.5% | -1899.8% | 15.4% | -261.4% | 14.7% | 112.1% | -422.3% | 20.5% | |
| EPS (Diluted) | 188.4% | 134.2% | -91.7% | -1865.5% | 14.5% | -254.5% | 16.4% | 109.9% | -484.8% | 26.8% | |
| Operating Cash Flow | 34.6% | -32.6% | -19.0% | -206.4% | 196.7% | -237.2% | 22.8% | 101.5% | -180.2% | 6199.9% | |
| Free Cash Flow | 135.3% | -305.1% | -107.9% | -52.3% | 80.0% | -500.2% | 25.9% | 53.4% | 24.9% | 145.7% | |
| R&D Expense | 31.1% | 35.1% | -10.4% | -33.9% | -11.8% | 17.3% | 11.4% | -1.8% | -3.7% | 3.0% | |
| SG&A Expense | 17.6% | -10.7% | 23.3% | -36.5% | -31.8% | 25.0% | 12.4% | 3.8% | 8.9% | -24.3% | |
| Total Assets | 4.2% | 13.0% | 28.3% | 4.3% | -7.1% | -45.4% | -7.7% | 0.2% | -5.8% | -3.0% | |
| Book Value / Share | 5.7% | 9.9% | 4.5% | -16.8% | -12.6% | -56.9% | -104.7% | 363.0% | -89.7% | -1212.8% | |
| Debt | -12.9% | 35.2% | 109.1% | 45.0% | -2.4% | 14.8% | -54.5% | 18.6% | -2.1% | 9.0% | |
| Diluted Shares | 1.9% | 1.0% | 2.5% | 1.9% | 0.5% | 0.6% | 1.7% | 22.4% | -5.0% | 7.3% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High14.41 / 35.00 / 125.94
P/S2.06
10Y Low / Med / High0.48 / 1.97 / 3.48
P/B-3.28
10Y Low / Med / High0.99 / 1.73 / 175.14
EV/EBITDAAt Loss
10Y Low / Med / High8.34 / 17.66 / 48.19
EV/Revenue3.78
10Y Low / Med / High0.75 / 3.07 / 5.60
P/FCF47.35
Intrinsic Value Models (per share)
Cash / Share
$0.61
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 35.00 | 15.61 | 125.94 | -8.27 | -10.69 | -2.49 | -2.39 | 14.41 | -5.29 | -8.89 | -3.37 | |
| P/S Ratio | 0.71 | 0.74 | 0.48 | 1.97 | 3.48 | 2.61 | 2.30 | 1.34 | 1.82 | 2.10 | 2.06 | |
| P/B Ratio | 1.66 | 1.54 | 0.99 | 1.37 | 1.73 | 3.31 | -56.23 | 15.14 | 175.14 | -19.16 | -3.28 | |
| EV/EBITDA | 15.89 | 17.66 | 17.37 | -74.97 | -572.80 | 41.86 | -9.99 | 8.34 | -40.46 | 48.19 | -15.24 | |
| EV/Revenue | 0.80 | 0.88 | 0.75 | 3.35 | 5.60 | 4.83 | 3.21 | 2.31 | 2.77 | 3.07 | 3.78 |
Analyst Estimates & Quality
Altman Z-Score
-0.85
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $121.6M | $130.7M | $150.3M |
| Net Income | -$44.7M | -$32.9M | -$40.4M |
| EPS | $-1.21 | $-0.88 | $-1.08 |
| # Analysts (EPS) | 2 | 1 | 1 |